Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic, New England Biolabs Partner on PCR Products

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic and New England Biolabs today announced an agreement for the provision of specific aptamer-based reagents to NEB for nucleic acid amplification and PCR products.

Under the terms of the deal, SomaLogic will provide certain SomaMers — which are specific protein binding reagents based on chemically modified aptamers developed by SomaLogic — to NEB to incorporate them into its products as reversible inhibitors of thermally active DNA polymerases used in PCR, the two firms said.

Financial and other terms of the agreement were not disclosed.

In a statement, Salvatore Russello, associate director of business development at NEB, said that there are many opportunities to improve the performance of thermally active DNA polymerase in PCR reactions.

"This agreement is thus of great value to NEB and is already being used to improve the application of DNA polymerases," such as NEB's OneTaq Hot Start product, he said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.